Transcutaneous delivery and thermostability of a dry trivalent inactivated influenza vaccine patch

Influenza and other Respiratory Viruses

Volumn 2, Issue 2, 2008, Pages 53-60

  Frolov, Vladimir G ^a   Seid Jr , Robert C ^a   Pool, Judith ^a   Odutayo, Olabisi ^a   Al Khalili, Mohammad ^a   Yu, Jianmei ^a   Frolova, Olga Y ^a   Vu, Hong ^a   Butler, Barbara A ^a   Look, Jee Loon ^a   Ellingsworth, Larry R ^a   Glenn, Gregory M ^a  

^a IOMAI Corporation   (United States)

Author keywords

Influenza vaccine; Thermostability; Transcutaneous immunization; Vaccine patch

Indexed keywords

IMMUNOGLOBULIN G ANTIBODY; INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; NITROGEN; TRIPLE VACCINE;

ARTICLE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG STABILITY; DRUG STORAGE; DRUG TOLERABILITY; ENVIRONMENTAL STRESS; FEMALE; FREEZING; IMMUNE RESPONSE; IMMUNOGENICITY; NONHUMAN; PRIORITY JOURNAL; ROOM TEMPERATURE; THERMOSTABILITY; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, CUTANEOUS; ANIMALS; ANTIBODIES, VIRAL; BACTERIAL TOXINS; DESICCATION; DOSAGE FORMS; DRUG STABILITY; DRUG STORAGE; ENTEROTOXINS; ESCHERICHIA COLI PROTEINS; FEMALE; GUINEA PIGS; IMMUNOGLOBULIN G; INFLUENZA VACCINES; VACCINES, INACTIVATED;

EID: 65249092048     PISSN: 17502640     EISSN: 17502659     Source Type: Journal    
DOI: 10.1111/j.1750-2659.2008.00040.x     Document Type: Article

References (24)

1. Glenn GM, Taylor DN, Li X, Frankel S, Montemarano A, Alving CR. Transcutaneous immunization: A human vaccine delivery strategy using a patch. Nat Med 2000; 6:1403-1406.
2. Glenn GM, Kenney RT. Transcutaneous immunization. in: Levine MM, Kaper JB, Rappuoli R, Liu M, Good M, eds. New Generation Vaccines, 3rd edn. New York: Marcel Dekker, Inc. 2004; 4010-412.
3. Glenn GM, Kenney RT, Ellingsworth LR, Frech SA, Hammond SA, Zoeteweij JP. Transcutaneous immunization and immunostimulant strategies: capitalizing on the immunocompetence of the skin. Expert Rev Vaccines 2003; 2:253-267.
4. Glenn GM, Kenney RT, Hammond SA, Ellingsworth LR. Transcutaneous immunization and immunostimulant strategies. Immunol Allergy Clin N Am 2003; 23:787-813.
5. Belyakov IM, Hammond SA, Ahlers JD, Glenn GM, Berzofsky JA. Transcutaneous immunization induces mucosal CTLs and protective immunity by migration of primed skin dendritic cells. J Clin Invest 2004; 113:998-1007.
6. Hammond SA, Walwender D, Alving CR, Glenn GM. Transcutaneous immunization: T-cell responses and boosting of existing immunity. Vaccine 2001; 19:2701-2707.
7. Glenn GM, Scharton-Kersten T, Vassell R, Matyas GR, Alving CR. Transcutaneous immunization with bacterial ADP-ribosylating exotoxins as antigens and adjuvants. Infect Immun 1999; 67:1100-1106.
8. Scharton-Kersten T, Yu J, Vassell R, O'Hagan D, Alving CR, Glenn GM. Transcutaneous immunization with bacterial ADP-ribosylating exotoxins, subunits, and unrelated adjuvants. Infect Immun 2000; 68:5306-5313.
9. Tierney R, Beignon AS, Rappuoli R, Muller S, Sesardic D, Partidos CD. Transcutaneous immunization with tetanus toxoid and mutants of Escherichia coli heat-labile enterotoxin as adjuvants elicits strong protective antibody responses. J Infect Dis 2003; 188:753-758.
10. Güereña-Burgueño F, Hall ER, Taylor DN et al. Safety and immunogenicity of a prototype enterotoxigenic Escherichia coli vaccine administered transcutaneously. Infect Immun 2002; 70:1874-1880.
11. Yu J, Cassels F, Scharton-Kersten T et al. Transcutaneous immunization using colonization factor and heat labile enterotoxin induces correlates of protective immunity for enterotoxigenic Escherichia coli. Infect Immun 2002; 70:1056-1068.
12. McKenzie R, Bourgeois AL, Frech SA et al. Transcutaneous immunization with the heat-labile toxin (LT) of enterotoxigenic Escherichia coli (ETEC): Protective efficacy in a double-blind, placebo-controlled challenge study. Vaccine 2007; 25:3684-3691.
13. Glenn GM, Villar CP, Flyer DC et al. Safety and immunogenicity of an ETEC vaccine patch containing heat-labile toxin: Use of skin pretreatment to disrupt the stratum corneum. Infect Immun 2007; 75:2163-2170.
14. Wood JM, Schild GC, Newman RW, Seagroatt V. An improved single- radial-immunodiffusion technique for the assay of influenza haemagglutinin antigen: Application for potency determinations of inactivated whole virus and subunit vaccines. J Biol Stand 1977; 5:237-247.
15. FDA. Draft Guidance for Industry, Stability Testing of Drug Substances and Drug Products. Rockville, MD: Food and Drug Administration, 1998.
16. Lucas TI, Bishara RH, Seevers RH. A stability program for the distribution of drug products. Pharm Technol 2004; 2:68-73.
17. ICH. Guidance for Industry, Q1D: Bracketing and Matrixing Designs for Stability Testing of New Drug Substances and Products. in: Food and Drug Administration, ed. Federal Register, 16 January, 2003; 2339-2340.
18. ICH. Q1A(R2): Stability Testing of New Drug Substances and Products (Second Revision). In: Food and Drug Administration, ed. Federal Register, 21 November, 2003; 65717-65718.
19. Zoeteweij J-P, Epperson DE, Porter JD et al. GM1-binding deficient exotoxin is a potent non-inflammatory broad-spectrum intradermal immunoadjuvant. J Immunol 2006; 177:1197-1207.
20. Halperin SA, Smith B, Mabrouk T et al. Safety and immunogenicity of a trivalent, inactivated, mammalian cell culture-derived influenza vaccine in healthy adults, seniors, and children. Vaccine 2002; 20:1240-1247.
21. Carpenter JF, Chang BS, Garzon-Rodriquez W, Randolph TW. Rational design of stable lyophilized protein formulations: Theory and practice. in: Carpenter JF, Manning MC, eds. Rational Design of Stable Protein Formulations. New York: Kluwer Academic/Plenum Publishers, 2002; 109-133.
22. Lee G. Spray-drying of proteins. in: Carpenter JF, Manning MC, eds. Rational Design of Stable Protein Formulations. New York, NY: Kluwer Academic/Plenum Publishers, 2002; 135-158.
23. Krell T, Manin C, Nicolai MC et al. Characterization of different strains of poliovirus and influenza virus by differential scanning calorimetry. Biotechnol Appl Biochem 2005; 3:241-246.
24. Luykx DM, Casteleijn MG, Jiskoot W, Westdijk J, Jongen PM. Physicochemical studies on the stability of influenza haemagglutinin in vaccine bulk material. Eur J Pharm Sci 2004; 23:65-75.